NCT00038207 - Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2005

Conditions

Soft Tissue SarcomaLymphomaLeukemiaWilms' TumorOsteosarcoma

Interventions

DRUG

Liposomal Vincristine

Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days

Trial Locations (1)

UT MD Anderson Cancer Center, Houston